View All Jobs
Our business is your health

At Regeneron we make it our business every day to bring innovative thinking to the challenge of discovering and developing new medicines. Our pursuit has one singular intent – to improve therapeutic outcomes for patients.

Our first approved product, ARCALYST® (rilonacept), an anti-inflammatory agent, has been available to patients in the U.S. since 2008.In late 2011, we launched EYLEA® (aflibercept) Injection, also known in the scientific literature as VEGF Trap-Eye and Intravitreal Aflibercept Injection.

more
Products

EYLEA® (aflibercept) Injection and ARCALYST® (rilonacept)

more
Responsibility

At Regeneron, we are committed to a better future. This promise is at the core of our mission to discover and develop new medicines, which allows us to deliver greater value to our patients, employees and communities.

more
Science

Regeneron was founded by physician scientists, and today, more than 20 years later, strong science remains at the heart of our capabilities and culture.

Through our original research we have discovered novel drug targets such as angiopoietins and neurotrophins, and we have developed product candidates to these targets as well as to others that have been validated by academic researchers or other pharmaceutical companies.We have pursued both novel and validated targets because we believe this is a strategy that balances risk and reward.

more

Reviews

Employees are "Satisfied"
3.7
120 Reviews
Culture & Values 3.669534
Work/Life Balance 3.23793
Senior Management 3.278731
Comp & Benefits 3.496365
Career Opportunities 3.157589
Leonard S. Schleifer President, CEO, and Director
%
Approve of the CEO 85 Ratings
Approve

Awards